Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Two-stage Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BR113 in Patients With Advanced Solid Tumors

NCT07753590 is registered in ClinicalTrials.gov with BioRay Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07753590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07753590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Two-stage Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BR113 in Patients With Advanced Solid Tumors
Lead sponsor
BioRay Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
December 31, 2030
Enrollment
258 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors